山鷹國際(600567.SH)及智源基金與雲印技術、質子科技簽訂工業具身項目戰略投資合作協議
格隆匯8月14日丨山鷹國際(600567.SH)公佈關於發起設立智源基金的進展暨簽訂戰略投資合作協議的公吿,基於各自優勢資源,山鷹國際控股股份公司與合作方雲印技術(深圳)有限公司(簡稱“雲印技術”)、武漢質子科技有限公司(簡稱“質子科技”)圍繞為造紙和包裝行業提供工業具身產品整體解決方案及相關產品與服務開展戰略投資合作,本次合作確立了項目合作的基本框架與原則,具體合作項目、實施細則等未盡事宜將另行簽訂相關合同或補充協議。山鷹國際、智源基金與雲印技術、質子科技簽訂了工業具身項目戰略投資合作協議。智源基金擬投資的合資公司尚處於籌備設立階段,尚未完成工商註冊。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.